As of January 22, 2025, Mereo BioPharma Group (MREO) has a market cap of $0.45 billion USD. According to our data, Mereo BioPharma Group is ranked No.6241 in global market value.
Year | Market Cap | %Change |
---|---|---|
Jan 22, 2025 | $0.45 B |
-16.57%
|
Dec 31, 2024 | $0.54 B |
51.52%
|
Dec 29, 2023 | $0.36 B |
208.00%
|
Dec 30, 2022 | $0.12 B |
-53.13%
|
Dec 31, 2021 | $0.25 B |
-55.31%
|
Dec 31, 2020 | $0.56 B |
9.15%
|
Dec 31, 2019 | $0.51 B |
100%
|
Name | Market Cap | Market cap difference | Regions |
---|---|---|---|
Adaptimmune Therapeutics
ADAP
|
$0.15 B |
0.000 M
|
UK
|
Blueprint Medicines
BPMC
|
$7.06 B |
-0.000 M
|
USA
|
Deciphera Pharmaceuticals
DCPH
|
$2.21 B |
2.213 B
|
USA
|
Karyopharm Therapeutics
KPTI
|
$84.09 M |
0.000 M
|
USA
|
MacroGenics
MGNX
|
$0.19 B |
-0.000 M
|
USA
|
Nektar Therapeutics
NKTR
|
$0.17 B |
0.000 M
|
USA
|
Protagonist Therapeutics
PTGX
|
$2.20 B |
-0.000 M
|
USA
|
Syndax Pharmaceuticals
SNDX
|
$1.20 B |
0.000 M
|
USA
|
TG Therapeutics
TGTX
|
$4.54 B |
0.000 M
|
USA
|
Zymeworks
ZYME
|
$1.01 B |
-0.000 M
|
Canada
|
Market Cap | = | MREO Stock Price | * | MREO Shares Outstanding |
= | $2.92 | * | 0.16 B | |
= | $0.45 B |